Pacific Biosciences of California
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 67.9% | 83.6% | 70.9% | 83.5% | 75.0% | 74.4% | 103.7% | 63.1% | 60.8% | 62.5% | 65.5% | 67.6% | 64.0% | |
| 32.1% | 16.4% | 29.1% | 16.5% | 25.0% | 25.6% | -3.7% | 36.9% | 39.2% | 37.5% | 34.5% | 32.4% | 36.0% | |
| 85.3% | 76.3% | 112.0% | 106.9% | 63.8% | 70.0% | 78.2% | 56.7% | 59.4% | 51.2% | 52.7% | 59.0% | 55.5% | |
| 78.0% | 78.8% | 112.7% | 127.4% | 109.5% | 106.2% | 108.1% | 91.0% | 80.9% | 76.3% | 83.8% | 85.6% | 81.4% | |
| 180.3% | 166.4% | 238.7% | 504.8% | 185.4% | 415.8% | 1,150.8% | 149.7% | 140.2% | 129.8% | 136.5% | 146.8% | 138.0% | |
| -148.1% | -150.0% | -209.6% | -488.3% | -160.3% | -390.1% | -1,154.5% | -112.8% | -101.0% | -92.3% | -102.0% | -114.4% | -102.1% | |
| 6.4% | 6.1% | 9.2% | 9.8% | 8.9% | 7.0% | 4.7% | 4.4% | 4.5% | 3.9% | 4.7% | 5.4% | 4.6% | |
| -139.3% | -141.8% | -201.4% | -481.3% | -151.9% | 6.9% | -1,147.6% | -105.4% | -97.9% | -90.0% | -21.8% | -114.6% | -82.0% | |
| -19.2% | -1.2% | 30.8% | – | -151.9% | 0.8% | -0.8% | 0.1% | 1.0% | 0.5% | 0.5% | 0.1% | 0.5% | |
| -120.1% | -140.5% | -201.4% | -481.3% | -151.9% | 6.0% | -1,146.8% | -105.4% | -98.9% | -90.4% | -22.3% | -114.7% | -82.5% | |
| -123.1% | -105.1% | -161.3% | -431.8% | -102.8% | 41.8% | -139.6% | -89.5% | -81.9% | -75.7% | -15.5% | -97.6% | -68.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.